Form 4: Dyne Therapeutics Director Sells Shares Under 10b5-1 Plan

Dyne Therapeutics director Dirk Kersten sold 129,672 shares of common stock for approximately $19.52 per share under a pre-arranged trading plan.

Summary

• Dirk Kersten, a Director of Dyne Therapeutics, Inc., disposed of 129,672 shares of common stock.
• The transaction occurred on March 11, 2026, and was executed pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. on November 11, 2025.
• The shares were sold at a weighted average price of $19.5151 per share, with individual transactions ranging from $18.88 to $19.87.
• Following this transaction, 4,644,386 shares of common stock are beneficially owned indirectly by ForDyne B.V., where Mr. Kersten holds a partnership role and is a member of the investment committee.
• Mr. Kersten disclaims beneficial ownership of the shares held by ForDyne B.V., except to the extent of his pecuniary interest therein.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative event due to insider selling, though mitigated by the presence of a 10b5-1 plan, which suggests a pre-planned, non-discretionary sale.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reactive decision, which can mitigate negative market perception of insider selling.

Negatives

• A director selling a significant number of shares (129,672) could be perceived by some investors as a signal of reduced confidence in the company's future prospects, despite being part of a pre-arranged plan.

Risks

• The market may react negatively to the news of a director selling shares, potentially leading to short-term stock price volatility.
• While the sale is planned, it represents a reduction in insider ownership, which some investors might interpret as a lack of alignment with long-term shareholder interests.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Dirk Kersten disclaims beneficial ownership of the shares held by ForDyne B.V., except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are common in the biotechnology sector. While a 10b5-1 plan indicates a pre-scheduled sale for liquidity or portfolio diversification, the market often scrutinizes such transactions for potential signals about management's confidence in the company's near-term prospects. This transaction is consistent with routine insider activity under a pre-arranged plan.

Related Party Transactions

• The shares are held indirectly by ForDyne B.V., which is jointly owned by Forbion Capital Fund IV Cooperatief U.A. and Forbion Growth Opportunities Fund II Cooperatief U.A.
• Dirk Kersten is a partner of Forbion Management B.V. and Forbion Growth II Management B.V., and a member of their investment committees, which may be deemed to have voting and dispositive power over the shares held by ForDyne B.V.

Stakeholder Impact

• Shareholders may interpret the director's sale as a potential signal regarding the company's valuation or future outlook, potentially influencing their investment decisions.

Key Dates

Keywords

Dyne Therapeutics, DYN, Insider Sale, Form 4, Dirk Kersten, 10b5-1 Plan, Beneficial Ownership, Common Stock, Director Transaction